Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma

Transplantation

Volumn 83, Issue 7, 2007, Pages 893-899

  Soejima, Yuji ^a   Taketomi, Akinobu ^a   Yoshizumi, Tomoharu ^a   Uchiyama, Hideaki ^a   Aishima, Shinich ^a   Terashi, Takahiro ^a   Shimada, Mitsuo ^b   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Des gamma carboxy prothrombin; Hepatocellular carcinoma; Living donor liver transplantation; Milan criteria

Indexed keywords

ALPHA FETOPROTEIN; BASILIXIMAB; CISPLATIN; CYCLOSPORIN A; DECARBOXYPROTHROMBIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER SIZE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DONOR SELECTION; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER METASTASIS; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; TREATMENT INDICATION; TUMOR VOLUME;

ADULT; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; NEPHRECTOMY; PATIENT SELECTION; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE AND ORGAN HARVESTING; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34247594879     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000259015.46798.ec     Document Type: Article

References (26)

1. Penn I. Hepatic transplantation for primary and metastasis cancer of the liver. Surgery 1991; 110: 726.
2. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1991; 214: 221.
3. Mazzafero V, Regalia E, Doci R, et al. Liver Transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 14: 728.
4. Yao FY, Bass NM, Nikolas B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-test principle and dropout from the waiting list. Liver Transplant 2002; 8: 873.
5. Shimada M, Yonemura Y, Ijichi H, et al. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value. Transplant Proc 2005; 37: 1177.
6. Nishizaki T, Ikegami T, Hiroshige S, et al. Small graft for living donor liver transplantation. Ann Surg 2001; 233: 577.
7. UNOS/OPTN policy 3.6.4.4. Available at http://www.optn.org. Accessed June 13, 2005.
8. Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396.
9. Shimada M, Yamashita Y, Hamatsu T, et al. The role of des-γ-carboxy prothrombin levels in hepatocellular carcinoma and liver tissues. Cancer Lett 2000; 159: 87.
10. Nagaoka S, Yatsuhashi H, Hamada H, et al. The des-γ-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 2003; 98: 2671.
11. Marrero JA, Su GL, Wei W, et al. Des-gamma carboxyprothrombin can differenciate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003; 37: 1114.
12. Koike Y, Shiratori Y, Sato S, et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. Cancer 2001; 91: 561.
13. Suehiro T, Sugimachi K, Matsumata T, et al. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Cancer 1994; 73: 2464.
14. Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001; 136: 25.
15. Gondolesi GE, Roayaie S, Munos U, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma Extending UNOS priority criteria. Ann Surg 2004; 239: 142.
16. Sarasin FP, Majno PE, Llovet JM, et al. Living donor liver transplantation for early hepatocellular carcinoma: a life expectancy and cost-effectiveness perspective. Hepatology 2001; 33: 1073.
17. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394.
18. Marsh JW, Dvorchik I, Subotin M, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 1997; 26: 444.
19. Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235: 533.
20. Kaihara S, Kiuchi T, Ueda M, et al. Living-donor live transplantation for hepatocellular carcinoma. Transplantation 2003; 75: S37.
21. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080.
22. Ravaioli M, Ercolani G, Cescon M, et al. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl 2004; 10: 1195.
23. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differenciated hepatocellular carcinoma. Ann Surg 2004; 239: 150.
24. Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma. Experience in Japan. Ann Surg 2004; 240: 451.
25. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707.
26. Suzuki M, Shiraha H, Fujikawa T, et al. Des-γ-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem 2005; 6409.